Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1465-1472

  Sanderink, Ger Jan ^a   Bournique, Bruno ^b   Stevens, Jeffrey ^b   Petry, Martine ^b   Martinet, Michel ^b  

^a SANOFI   (France)

^b Rhône Poulenc Rorer ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; AMITRIPTYLINE; CLOMIPRAMINE; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DIAZEPAM; DICLOFENAC; ENOXACIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; NICERGOLINE; O DEMETHYLASE; PROPOFOL; QUININE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESORUFIN DERIVATIVE; RILUZOLE; URIDINE DIPHOSPHATE GALACTOSE;

ARTICLE; B LYMPHOBLAST; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; PRIORITY JOURNAL;

EID: 0030924553     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A. AND BIRKETT, D. J.: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36: 521-530, 1993.
2. BACK, D. J., STEVENSON, P. AND TJIA, J. F.: Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol. 28: 166-170, 1989.
3. BENSIMON, G., LACOMBLEZ, L., MEININGER, V. AND THE ALS/RILUZOLE STUDY GROUP: A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330: 585-591, 1994.
4. BERCHTY, G., VANDEL, S., VANDEL, B., ALLERS, G. AND VOLMAT, R.: Fluvoxamine-tricyclic antidepressant interaction. Eur. J. Clin. Pharmacol. 40: 119-120, 1991.
5. BIRKETT, D. J., MACKENZIE, P. I., VERONESE, M. E. AND MINERS, J. O.: In vitro approaches can predict human drug metabolism. Trends Pharmacol. Sci. 14: 292-294, 1993.
6. BOOBIS, A. R., LYNCH, A. M., MURRAY, S., DE LA TORRE, R., SOLANS, A., FARRE, M., SEGURA, J., GOODERHAM, N. J. AND DAVIES, D. S.: CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res. 54: 89-94, 1994.
7. BRØSEN, K., SKJELBO, E., RASMUSSEN, B. B., POLSEN, H. E. AND LOFT, S.: Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol. 45: 1211-1214, 1993.
8. CHANG, T., LEVINE, M. AND BELLWARD, G. D.: Selective inhibition of rat hepatic microsomal cytochrome P-450. II. Effect of in vitro administration of cimetidine. J. Pharmacol. Exp. Ther. 260: 1450-1455, 1992.
9. DISTLERATH, L., REILLY, P., MARTIN, M., DAVIS G. C., WILKINSON, G. R. AND GUENGERICH, F. P.: Purification and characterization of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260: 9057-9067, 1985.
10. DOBLE, A.: The pharmacology and mechanism of action of riluzole. Neurology 47: S233-S241, 1996.
11. EBNER, T. AND BURCHELL, B.: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug. Metab. Dispos. 21: 50-55, 1993.
12. EDWARDS, D. J., BOWLES, S. K., SVENSSON, C. K. AND RYBAK, M. J.: Inhibition of drug metabolism by quinolone antibiotics. Clin. Pharmacokinet. 15: 194-204, 1988.
13. FUHR, U., DOEHMER, J., BATTULA, N., WOELFEL, C., KUDLA, C. AND KEITA, Y.: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem. Pharmacol. 43: 225-235, 1992.
14. GONZALEZ, F. J.: Human cytochromes P450: Problems and prospects. Trends Pharmacol. Sci. 13: 346-352, 1992.
15. GONZALEZ, F. J. AND IDLE, J. R.: Pharmacogenetic phenotyping and genotyping. Clin. Pharmacokinet. 26: 59-70, 1994.
16. GRANT, D. M., CAMPBELL, M. E., TANG, B. K. AND KALOW, W.: Biotransformation of caffeine by microsomes from human liver. Biochem. Pharmacol. 36: 1251-1260, 1987.
17. GUENGERICH, F. P., MARTIN, M., BEAUNE, P., KREMERS, P., WOLFF, T. AND WAXMAN, D. J.: Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060, 1986.
18. GUENGERICH, F. P. AND SHIMADA, T.: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4: 391-407, 1991.
19. KNODELL, R. G., BROWNE, D. G., GWOZDZ, G. P., BRIAN, W. R. AND GUENGERICH, F. P.: Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101: 1680-1691, 1991.
20. KNODELL, R. G., HALL, S. D., WILKINSON, G. R. AND GUENGERICH, F. P.: Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241: 1112-1119, 1987.
21. KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. AND MEYER, U.: High performance liquid Chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase and dextromethorphan O-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Anal. Biochem. 162: 24-32, 1987.
22. LACOMBLEZ, L., BENSIMON, G., LEIGH, P. N., GUILLET, P. AND MEININGER, V., for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425-1431, 1996.
23. LEMOINE, A., GAUTIER, J. C., AZOULAY, D., KIFFEL, L., BELLOC, C., GUENGERICH, F. P., MAUREL, P., BEAUNE, P. AND LEROUX, J. P.: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol. Pharmacol. 43: 827-832, 1993.
24. MEIER, U. T., KRONBACH, T. AND MEYER, U. A.: Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 151: 286-291, 1985.
25. MURRAY, M. AND FIELD, S. L.: Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochem. Pharmacol 43: 2065-2071, 1992.
26. ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. AND TSUTSUI, M.: Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450S and human liver microsomes. Xenobiotica 26: 681-693, 1996.
27. PEARCE, R., GREENWAY, D. AND PARKINSON, A.: Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol and testosterone oxidation. Arch. Biochem. Biophys. 298: 211-225, 1992.
28. PECK, C., TEMPLE, R. AND COLLINS, J.: Understanding the consequences of concurrent therapies. JAMA 268: 1550-1552, 1993.
29. PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. AND YANG, C. S.: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450llE1. Chem. Res. Toxicol. 3: 566-576, 1991.
30. RAUCY, J. L., LASKER, J. M., LIEBER, C. S. AND BLACK, M.: Acetaminophen activation by human liver microsomes P450llE1 and P4501A2. Arch. Biochem. Biophys. 271: 270-283, 1989.
31. SATTLER, M., GUENGERICH, F. P., YUN, C. H., CHRISTIANS, U. AND SEWING, K. F.: Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20: 753-761, 1992.
32. SMITH, S. R. AND KENDALL, M. J.: Ranitidine versus cimetidine: A comparison of their potential to cause clinically important drug interactions. Clin. Pharmacokinet. 15: 44-56, 1988.
33. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. AND MINERS, J. O.: Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 46: 1975-1981, 1993a.
34. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. AND MINERS, J. O.: Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265: 401-407, 1993b.
35. VERONESE, M., MACKENZIE, P. I., DOECKE, C., MCMANUS M. E., MINERS, J. O. AND BIRKETT, D. J.: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175: 1112-1118, 1991.
36. WRIGHTON, S., STEVENS, J., BECKER, G. AND VANDENBRANDEN, M.: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993.
37. YUN, C.-H., SHIMADA, T. AND GUENGERICH, F.: Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol. 40: 679-685, 1991.
38. ZAND, R., NELSON, S. D., SLATTERY, J. T., KALHORN, T. F., ADAMS, S. P. AND WRIGHT, J. M.: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharmacol. Ther. 54: 142-149, 1993.